UNASSIGNED: 5096 Background: To evaluate efficacy and safety of rAd- @entity876 in combination with radiotherapy in treatment of unresectable @entity5 . METHODS: @entity1 with primary unresectable @entity957 of FIGO late-stage IIband IIIb were intratumorally injected with rAd- @entity876 of 1 ' 10(12) virus particles (vp) once a week for 6 weeks in combination with concurrently pelvic RT plus brachytherapy at point A at a total dose of 73.9 SD 3.8 Gy. RESULTS: From March 2002 to May 2010, 31 @entity1 , 14 @entity1 in IIb and 17 @entity1 in IIIb of locally advanced @entity957 , were enrolled into this phase II study. All @entity1 experienced complete response (CR) immediately after treatment. No local and pelvic recurrence was found during follow-up period. Distant @entity3 occurred in 2 cased (6.5%). The median survival time was 96 months (95% CI, 79 to 112 months). Five-years of survival rate was 85.7%, which is 30.0% higher than 55.3% of survival rate from a study including 140,000 cases with @entity5 treated using radiotherapy alone. No dose-limiting @entity137 or serious adverse events appeared, except for transient @entity221 after rAd- @entity876 administration. CONCLUSIONS: RAd- @entity876 in combination with radiotherapy was safe and effective in treatment of unresectable @entity5 .

Recombinant adenovirus- XXXX (rAd- @entity876 ) in combination with radiotherapy for treating @entity5 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage I-IV of cervical cancer', 'cervical cancer'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma of the cervix'] @entity876 :: ('7157', 'Gene') :: ['p53'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever']
@entity876 :: (7157,Gene) :: ['p53']
